AlphaRx continues to build up Indaflex for the Chinese market AlphaRx.

AlphaRx continues to build up Indaflex for the Chinese market AlphaRx, Inc. , has been recommended by Cypress Biosciences , its advancement partner for Indaflex, that Cypress isn’t funding advancement of Indaflex. Notwithstanding to the termination of most Indaflex activity in the U tadalafil 20mg side effects .S.A., AlphaRx continues to develop Indaflex for the Chinese marketplace. AlphaRx is operating diligently with its regulatory consultants in the preparation for submission of a CTA with the China SFDA to be able to begin individual trials in China. These preparations are proceeding on routine.

tadalafil 20mg side effects

announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective medication candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, July 10 – 14 Oregon, 2010. On Wednesday, July 14, 2010, Dr. Joseph Schwarz, Chief Scientist of AlphaRx, can make an oral podium display of GAI-122 injectable nanoemulsion for neuroprotection. The results conclude that, based on the neuroprotective properties of GAI-122 and the increased focus of GAI-122 in the brain after parenteral delivery in accordance with oral dosing, it is fair to expect an injectable type of GAI-122 based on a nanoemulsion, provides the required protection against damage to cognitive and behavioral features in humans experiencing several ischemic disorders..